Grognet J M, Istin M, Zanotti A, Mailland F, Coppi G
Service of Pharmacology and Immunology, DRIPP, Gif-sur-Yvette, France.
Drugs Exp Clin Res. 1991;17(6):309-12.
The pharmacokinetic profile of a single dose (6 mg/kg) of alpha-dihydroergokryptine (alpha-DHEK) was established after oral administration in monkeys using a radio-immunoassay technique for non-metabolized drug. alpha-DHEK showed a plasma profile according to an open three-compartment pharmacokinetic model with a long half-life (mean = 5.787 h). The disposition of alpha-DHEK involves a fast absorption, a slow distribution phase and a slow elimination phase. alpha-DHEK showed an high total clearance and distribution volume; the drug is largely metabolized, as concluded from the very low urinary excretion.
采用放射免疫分析技术测定未代谢药物,在猴口服单剂量(6毫克/千克)α-二氢麦角隐亭(α-DHEK)后确定其药代动力学特征。α-DHEK的血浆特征符合开放三室药代动力学模型,半衰期较长(平均=5.787小时)。α-DHEK的处置涉及快速吸收、缓慢分布阶段和缓慢消除阶段。α-DHEK显示出高总清除率和分布容积;从极低的尿排泄量得出,该药物大部分被代谢。